Anti-PD1 Response Prediction Dream Challenge
LEARN MORE While durable responses and prolonged survival have been demonstrated in some lung cancer patients treated with immuno-oncology (I-O) anti-PD-1 therapy,
COVID-19 EHR DREAM Challenge
LEARN MORE The rapid rise of COVID-19 has challenged healthcare globally. Due to the importance and emergent need for better understanding of
CTD2 Chemosensitivity DREAM Challenge
Learn More The Columbia CTD2 Center developed PANACEA (Pancancer Analysis of Chemical Entity Activity), a comprehensive repertoire of dose response curves and
Metadata Automation DREAM Challenge
Learn More We aim to significantly lower the burden of adding coherent metadata annotations across the data ecosystem to streamline and enable
BEAT-PD DREAM Challenge
Learn More Recent advances in mobile health have demonstrated great potential to leverage sensor-based technologies for quantitative, remote monitoring of health and
CTD^2 BeatAML DREAM Challenge
Learn More The goal of the Beat AML DREAM Challenge is to define patient subpopulations tailored to individual treatments by discovering (genomic
CTD^2 Pancancer Drug Activity DREAM Challenge
Learn More Over the course of two years, the Columbia CTD2 Center developed PANACEA (Pancancer Analysis of Chemical Entity Activity), a comprehensive
RA2 DREAM Challenge
Learn More The purpose of the RA2-DREAM Challenge is to develop an automated method to quickly and accurately quantify the degree of
EHR DREAM Challenge – Patient Mortality Prediction
Learn More Healthcare institutions are attempting to move away from a rules-based approach to clinical care, toward a more data-driven model of
Allen Institute Cell Lineage Reconstruction DREAM Challenge
Learn More The advent of new CRISPR-based molecular tools allows the reconstruction of cell lineages based on the phylogenetical analysis of DNA